OVERALL - ABSTRACT The Karmanos Cancer Institute (KCI), founded in 1943, is a not-for-profit, cancer-only research and patient care organization in partnership with Wayne State University (WSU) in Michigan. The designation by the NCI as a Comprehensive Cancer Center was achieved in 1978. KCI operates its wholly-owned, free-standing, cancer hospital and ambulatory clinics (KCC) in Detroit and in Farmington Hills, a suburban location. As a member of McLaren Health Care (MHC), a not-for profit health care corporation, KCI is also responsible for cancer research, quality of care, and cancer care operations in all facilities owned and operated by MHC. Our catchment area covers 46 of Michigan?s 83 counties with a population of 6.7 million people. This catchment area is home to 95% of our patients, and KCI sees one-third of all new cancer patients in the catchment area. The Southeast region of our catchment area includes the metropolitan Detroit, defined as a tri-county area (Wayne, Oakland, Macomb) and home to 3.86 million residents. The city of Detroit is the largest city in the state (672,000 residents). Detroit is a resource-challenged area, with a median household income of $27,838 and 37.9% of residents living below poverty level, compared to 16.7% in the state of Michigan. The majority of census tracts in the city of Detroit are medically underserved areas based on HRSA definitions. About 79% of Detroit residents identify as African American, a group that disproportionately carries KCI catchment area?s cancer burden. In 2018, KCI physicians saw approximately 12,000 new cancer patients (including approximately 8,000 analytic cases), with approximately 15% representing minority groups. The annual number of new cancer cases in these 46 counties is approximately 39,000 and has not changed significantly since 2014. In FY19, our minority accrual to interventional treatment protocols was 24.2%. We have a long standing scientific and patient care commitment to the African American population of southeastern Michigan, as exemplified in the broad array of studies focused on molecular, therapeutic, and social disparities. This application profiles the strengths and successes of our four scientific Programs, Tumor Biology and Microenvironment (TBM, 01), Molecular Imaging (MI, 02), Molecular Therapeutics (MT, 03), and Population Studies and Disparities Research (PSDR, 04). The research efforts of these Programs is supported by nine Shared Resources (Cores), including one developing Core. As of December 2019, KCI?s 135 scientific members have secured total annual direct project funding of $ 63,162,159 (an increase of 12.3% from 2015) of which $21,864,688 is peer reviewed funding and $11,743,830 is from the NCI.
In 2020, there will be an estimated 1.8 million new cancer cases diagnosed and 606,520 cancer deaths in the United States (source: American Cancer Society). The Karmanos Cancer Institute is a not-for-profit, cancer- only research and patient care organization whose mission is to be a transformative leader in cancer care, research, and education through courage, commitment and compassion. Key to achieving this mission is KCI?s research effort, which is conducted among four transdisciplinary Programs, organized to integrate basic, translational, and clinical research with population research-based cancer control activities.
|Bock, Cathryn H; Jay, Allison M; Dyson, Gregory et al. (2018) The effect of genetic variants on the relationship between statins and breast cancer in postmenopausal women in the Women's Health Initiative observational study. Breast Cancer Res Treat 167:741-749|
|Hastert, T A; de Oliveira Otto, M C; Lê-Scherban, F et al. (2018) Association of plasma phospholipid polyunsaturated and trans fatty acids with body mass index: results from the Multi-Ethnic Study of Atherosclerosis. Int J Obes (Lond) 42:433-440|
|Park, Hyo K; Schildkraut, Joellen M; Alberg, Anthony J et al. (2018) Benign gynecologic conditions are associated with ovarian cancer risk in African-American women: a case-control study. Cancer Causes Control 29:1081-1091|
|Heyza, Joshua; Lei, Wen; Watza, Donovan et al. (2018) Identification and characterization of synthetic viability with ERCC1 deficiency in response to interstrand crosslinks in lung cancer. Clin Cancer Res :|
|Mittal, Sandeep; Klinger, Neil V; Michelhaugh, Sharon K et al. (2018) Alternating electric tumor treating fields for treatment of glioblastoma: rationale, preclinical, and clinical studies. J Neurosurg 128:414-421|
|Paximadis, Peter; Beebe-Dimmer, Jennifer L; George, Julie et al. (2018) Comparing Treatment Strategies for Stage I Small-cell lung Cancer. Clin Lung Cancer 19:e559-e565|
|Su, Yongwei; Li, Xinyu; Ma, Jun et al. (2018) Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo. Biochem Pharmacol 148:13-26|
|Bonomi, Robin; Popov, Vadim; Laws, Maxwell T et al. (2018) Molecular Imaging of Sirtuin1 Expression-Activity in Rat Brain Using Positron-Emission Tomography-Magnetic-Resonance Imaging with [18F]-2-Fluorobenzoylaminohexanoicanilide. J Med Chem 61:7116-7130|
|Teslow, Emily A; Bao, Bin; Dyson, Greg et al. (2018) Exogenous IL-6 induces mRNA splice variant MBD2_v2 to promote stemness in TP53 wild-type, African American PCa cells. Mol Oncol 12:1138-1152|
|Modi, Dipenkumar; Al-Kadhimi, Zaid; Chen, Wei et al. (2018) A phase II study of tacrolimus and thymoglobulin as graft-versus-host-disease prophylaxis in related donor allogeneic hematopoietic cell transplantation. Am J Hematol 93:E96-E98|
Showing the most recent 10 out of 826 publications